JP2016540738A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540738A5
JP2016540738A5 JP2016526801A JP2016526801A JP2016540738A5 JP 2016540738 A5 JP2016540738 A5 JP 2016540738A5 JP 2016526801 A JP2016526801 A JP 2016526801A JP 2016526801 A JP2016526801 A JP 2016526801A JP 2016540738 A5 JP2016540738 A5 JP 2016540738A5
Authority
JP
Japan
Prior art keywords
inhibitor
prostate cancer
pharmaceutical composition
composition according
akr1c3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540738A (ja
JP6548641B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/062455 external-priority patent/WO2015065919A1/en
Publication of JP2016540738A publication Critical patent/JP2016540738A/ja
Publication of JP2016540738A5 publication Critical patent/JP2016540738A5/ja
Priority to JP2019116833A priority Critical patent/JP6974392B2/ja
Application granted granted Critical
Publication of JP6548641B2 publication Critical patent/JP6548641B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526801A 2013-10-28 2014-10-27 転移性前立腺癌の治療 Expired - Fee Related JP6548641B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019116833A JP6974392B2 (ja) 2013-10-28 2019-06-25 転移性前立腺癌の治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361896250P 2013-10-28 2013-10-28
US61/896,250 2013-10-28
US201361914389P 2013-12-11 2013-12-11
US61/914,389 2013-12-11
PCT/US2014/062455 WO2015065919A1 (en) 2013-10-28 2014-10-27 Treatment of metastatic prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019116833A Division JP6974392B2 (ja) 2013-10-28 2019-06-25 転移性前立腺癌の治療

Publications (3)

Publication Number Publication Date
JP2016540738A JP2016540738A (ja) 2016-12-28
JP2016540738A5 true JP2016540738A5 (enExample) 2017-11-30
JP6548641B2 JP6548641B2 (ja) 2019-07-24

Family

ID=53004994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016526801A Expired - Fee Related JP6548641B2 (ja) 2013-10-28 2014-10-27 転移性前立腺癌の治療
JP2019116833A Expired - Fee Related JP6974392B2 (ja) 2013-10-28 2019-06-25 転移性前立腺癌の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019116833A Expired - Fee Related JP6974392B2 (ja) 2013-10-28 2019-06-25 転移性前立腺癌の治療

Country Status (5)

Country Link
US (2) US20170315127A1 (enExample)
EP (1) EP3062808B1 (enExample)
JP (2) JP6548641B2 (enExample)
CN (1) CN105899223A (enExample)
WO (1) WO2015065919A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2449112A1 (en) 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (scid)
JP6548641B2 (ja) 2013-10-28 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 転移性前立腺癌の治療
US10774387B2 (en) * 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2016179002A1 (en) * 2015-05-01 2016-11-10 The Regents Of The University Of California Compositions and methods for treatment of cancer
AU2016315852B2 (en) * 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
WO2017048197A1 (en) * 2015-09-16 2017-03-23 Agency For Science, Technology And Research Use of niclosamide in the treatment of p53-deficient cells
WO2017062505A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017120218A1 (en) * 2016-01-04 2017-07-13 The Regents Of The University Of Colorado, A Body Corporate Treatment of prostate cancer cells with fat oxidation inhibitors and enzalutamide
EP3464623B1 (en) * 2016-06-02 2021-09-01 Sint-Augustinus Androgen receptor splice variants and androgen deprivation therapy
US20200315996A1 (en) * 2016-06-02 2020-10-08 Board Of Trustees, Southern Illinois University Treatment of Endometriosis and Niclosamide Derivatives
US20200031848A1 (en) 2016-12-19 2020-01-30 Hoffmann-La Roche Inc. Ar-v7 inhibitors
EP3570837A4 (en) * 2017-01-19 2020-10-21 The Regents of The University of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANDROGEN-INDEPENDENT CANCER
WO2018183823A1 (en) * 2017-03-31 2018-10-04 Hera Testing Laboratories, Inc. Novel immunodeficient rat for modeling human cancer
RU2673816C1 (ru) * 2017-10-16 2018-11-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2696288C2 (ru) * 2017-10-16 2019-08-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
EP3709988A1 (en) * 2017-11-14 2020-09-23 Institut Regional du Cancer de Montpellier (ICM) Association of actives for treating prostate cancer
CN109836499A (zh) * 2017-11-27 2019-06-04 益善生物技术股份有限公司 抗人雄激素受体剪接变异体7的单克隆抗体及其应用
CN108187067A (zh) * 2018-01-09 2018-06-22 中国人民解放军第三0九医院 ITCNs组装体负载抗肿瘤化合物的应用
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
US20210222228A1 (en) * 2018-08-26 2021-07-22 Cardiff Oncology, Inc. Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors
US12318386B2 (en) 2018-09-07 2025-06-03 Karyopharm Therapeutics Inc. Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
CN109234393A (zh) * 2018-09-30 2019-01-18 上海交通大学医学院附属仁济医院 一种用于检测转移性去势抵抗性前列腺癌的基因探针组合物及试剂盒
JP2022506513A (ja) * 2018-11-01 2022-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン媒介性疾患の処置のための化合物、組成物、および方法
HUP1900281A1 (hu) * 2019-08-06 2021-03-01 Toxie Europe Intelligens Kemiai Szenzorokat Kutato Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
BR112022009457A2 (pt) * 2019-11-18 2022-08-16 Univ California Inibidores duplos de receptor androgênico/akr1c3
US20230005594A1 (en) * 2019-12-06 2023-01-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Clinical decision support for personalized adaptive prostate cancer therapy
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
TWI915409B (zh) * 2020-09-02 2026-02-21 大陸商深圳艾欣達偉醫藥科技有限公司 一種akr1c3檢測方法、檢測akr1c3的診斷試劑盒及其用途
WO2022212631A1 (en) * 2021-03-31 2022-10-06 Taiho Pharmaceutical Co., Ltd. Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist
WO2022250466A1 (ko) * 2021-05-27 2022-12-01 사회복지법인 삼성생명공익재단 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물
CN115721720A (zh) * 2021-08-31 2023-03-03 北京大学 Kras抑制剂与akr抑制剂联用在对抗肿瘤细胞耐药性中的应用
US20240122922A1 (en) * 2022-09-26 2024-04-18 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors
CN115721629B (zh) * 2022-10-31 2024-02-20 西安交通大学 多西他赛与恩杂鲁胺联合用药pH响应型铁-铜磁性纳米载药系统及其制备和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US20030144312A1 (en) 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
US20070009533A1 (en) 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20090035389A1 (en) 2007-02-23 2009-02-05 Specigen Inc. Targeted protein cages
GB2451875B (en) * 2007-08-15 2012-05-16 Mono Pumps Ltd Filtration system
US20090208493A1 (en) 2007-11-27 2009-08-20 Stc. Unm Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
WO2012142208A1 (en) * 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
ES2647072T3 (es) * 2011-04-18 2017-12-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Niclosamida para el tratamiento de la metástasis en el cáncer
US9346803B2 (en) * 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
KR101434461B1 (ko) 2011-10-21 2014-09-01 한국생명공학연구원 2-하이드록시아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
DK2945628T3 (da) 2013-01-15 2020-05-04 Aragon Pharmaceuticals Inc Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
JP6548641B2 (ja) 2013-10-28 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 転移性前立腺癌の治療
CN104771386A (zh) 2014-01-10 2015-07-15 中国科学院广州生物医药与健康研究院 苯甲酰胺类化合物及其应用
WO2016077787A1 (en) 2014-11-13 2016-05-19 Aeromics, Llc Novel methods
WO2016179002A1 (en) 2015-05-01 2016-11-10 The Regents Of The University Of California Compositions and methods for treatment of cancer
CN105566147B (zh) 2015-12-07 2018-03-09 北京信德润兴科技有限公司 一种化合物及其制备方法和用途及相应的靶向给药系统和化疗药物
EP3570837A4 (en) 2017-01-19 2020-10-21 The Regents of The University of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANDROGEN-INDEPENDENT CANCER

Similar Documents

Publication Publication Date Title
JP2014515373A5 (enExample)
WO2012079092A3 (en) Testosterone undecanoate compositions
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
NZ747657A (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
JP2017529382A5 (enExample)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2020516646A5 (enExample)
HK1198869A1 (en) Combination treatments for hepatitis c
JP2014516942A5 (enExample)
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
JP2017506624A5 (enExample)
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
EP2248519A3 (en) Non-mucoadhesive film dosage forms
JP2017537936A5 (enExample)
JP2012502047A5 (enExample)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2013541583A5 (enExample)
JP2015531373A5 (enExample)
JP2018522920A5 (enExample)
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.
JP2014504636A5 (enExample)
JP2016505050A5 (enExample)
JP2011500589A5 (enExample)